Rapport Therapeutics, Inc.

Rapport Therapeutics (RAPP) shows no material red flags in our 90-day monitoring window—zero cyber incidents, zero bankruptcy/delisting/restatement filings, and no officer departures detected. However, low signal in a short window does not indicate low risk; biotech equity structures and financing activity often drive shareholder returns in ways that 8-K alerts alone cannot capture. The full $49 Report extends analysis across 12 months of SEC filings, adds a dilution risk score based on option grants and warrant exercises, maps financing history, and surfaces AI-flagged risk signals in management disclosure language that our real-time pipeline cannot yet surface. This deeper context is essential for investors evaluating early-stage therapeutics where capital structure and burn rate dynamics matter as much as clinical progress.